Oxford Contrast offers a first-in-class in-vivo diagnostic platform that provides earlier and more precise diagnosis in a range of major diseases, including multiple sclerosis and brain metastasis.
Furthermore, the technology enables monitoring of disease progression and evaluation of response to treatment. Our platform technology represents a fundamental breakthrough from existing non-specific MRI contrast agents, by using an active molecular targeting approach. Existing agents can never, and will never, detect pathology as early in disease progression as Oxford Contrast’s new technology.
Latest news
- We presented at the 11th Annual MassBio event in Massachusetts.
- Oxford Contrast are pleased to announce that we are now members of the Oxfordshire Bioscience Network.
Brochure
- Download the executive summary here (PDF file, 2Mb, requires Adobe Reader or similar).